

Press release 2015-04-07

WntR clarifies data expected from the phase 1 trial

WntResearch AB today announces clarification on what kind of data can be expected from the current phase 1 dose escalation study in patients suffering from colon, breast and prostate cancer and explains on why data will be presented as a press release in time for ASCO (American Society of Clinical Oncology) instead as on ASCO itself.

As previously announced WntResearch had planned to present the first results from the currently ongoing Phase 1 dose escalating study with Foxy-5 at the ASCO-conference in late May. However, although the abstract was not selected for presentation, the company will still present the results of the phase 1 study (dose levels 1-8) as a press release as soon as the data is available. The reason why the abstract was not selected for presentation is not declared by ASCO, but it is very likely that the scientific committee found it to be lacking new data since it was submitted before completion of the study and thus before there were any final data to report.

The Phase 1 study is soon to be completed on dose level 8 as planned and Foxy-5 has not revealed any toxicity at any administered dose so far. As soon as all data have been collected and analysed the results will be presented in a final report that will include toxicity data from all 8 doses of Foxy-5. The report will also include data on pharmacokinetic and pharmacodynamic parameters such as biomarkers, circulating tumour cells and changes in gene expression. A summary of the report will be made public.

The Phase 1 study has only been allowed to enrol patients with metastatic disease for whom there was no other treatment (normal procedure), which means that one cannot expect to see any effects on metastatic development in this study. Anti-metastatic effects of Foxy-5 will be in focus in the planned Phase 2 study.

CEO Nils Brünner clarifies, "We are sorry that our recent information on the currently conducted phase 1 study has created confusion and speculations. With this new press release, we want to ensure that we are not in the possession of any negative data on Foxy-5 in clinical trials. We look very much forward to finalizing the Phase 1, and to make the results public from this dose escalation study. Then we will initiate the Phase 1b study to create the best possible conditions for the Phase 2 study which we intend to start in late fall 2015."

For additional information please contact:

Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: + 45 2614 4708

About WntResearch

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.